COVID-19大流行对美国丙型肝炎结局的长期影响模型研究
该微模拟研究评估COVID-19疫情扰乱HCV诊疗服务对美国丙型肝炎结局的10年影响。与无疫情情景相比,若疫情扰乱后不恢复至疫情前诊疗水平,每10万人中将减少1060例确诊病例、增加21例肝硬化和16例肝相关死亡,仅3%确诊病例启动治疗,<1%实现持续病毒学应答。
要点
- 疫情扰乱HCV诊疗可导致确诊减少、肝硬化和肝相关死亡增加。
- 若疫情后不恢复诊疗水平,仅3%确诊病例启动治疗,<1%实现SVR。
- 即使18个月扰乱后恢复至疫情前水平,确诊和SVR比例仍低于无疫情情景。
核心结论
- COVID-19大流行对HCV诊疗的扰乱可能导致美国HCV相关肝硬化和肝相关死亡增加,需重新投入资源加强筛查、链接和治疗。
研究设计与样本
- 微模拟模型估计COVID-19医疗中断对HCV结局的10年影响,并与无疫情反事实情景比较。
- 假设2020年3月起18个月HCV诊疗中断,之后筛查、链接和治疗以不同水平恢复至2030年3月,并分析12和24个月中断的替代情景。
主要发现
- 与无疫情情景相比,若疫情后不恢复至疫情前HCV诊疗水平,每10万人中估计减少1060例确诊病例、增加21例肝硬化和16例肝相关死亡。
- 在该情景下,仅3%确诊病例启动治疗,<1%实现持续病毒学应答(SVR)。
- 与无疫情情景相比,最佳情景(18个月中断后恢复至疫情前水平)下确诊感染比例和实现SVR比例仍较小。
临床怎么用
- 临床应重视COVID-19疫情后HCV筛查、链接至 care 和治疗服务的恢复与加强,以减少肝硬化和肝相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic disrupted access to and uptake of hepatitis C virus (HCV) care services in the United States. It is unknown how substantially the pandemic will impact long-term HCV-related outcomes. METHODS: We used a microsimulation to estimate the 10-year impact of COVID-19 disruptions in healthcare delivery on HCV outcomes including identified infections, linkage to care, treatment initiation and completion, cirrhosis, and liver-related death. We modeled hypothetical scenarios consisting of an 18-month pandemic-related disruption in HCV care starting in March 2020 followed by varying returns to pre-pandemic rates of screening, linkage, and treatment through March 2030 and compared them to a counterfactual scenario in which there was no COVID-19 pandemic or disruptions in care. We also performed alternate scenario analyses in which the pandemic disruption lasted for 12 and 24 months. RESULTS: Compared to the "no pandemic" scenario, in the scenario in which there is no return to pre-pandemic levels of HCV care delivery, we estimate 1060 fewer identified cases, 21 additional cases of cirrhosis, and 16 additional liver-related deaths per 100 000 people. Only 3% of identified cases initiate treatment and <1% achieve sustained virologic response (SVR). Compared to "no pandemic," the best-case scenario in which an 18-month care disruption is followed by a return to pre-pandemic levels, we estimated a smaller proportion of infections identified and achieving SVR. CONCLUSIONS: A recommitment to the HCV epidemic in the United States that involves additional resources coupled with aggressive efforts to screen, link, and treat people with HCV is needed to overcome the COVID-19-related disruptions.
引用
- Barocas JA, Savinkina A, Lodi S, et al. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022. PMID: 34499124. doi:10.1093/cid/ciab779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。